Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Cutia Therapeutics's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was HK$163.7 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$282.5 Mil.
Cutia Therapeutics (HKSE:02487) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Cutia Therapeutics Selling, General, & Admin. Expense Related Terms
Cutia Therapeutics Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics Selling, General, & Admin. Expense Chart
HKSE:02487 vs VRTX, REGN, MRNA: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Cutia Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's Selling, General, & Admin. Expense falls into.
Cutia Therapeutics Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$282.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of HK$282.5 Mil mean?
Cutia Therapeutics (HKSE:02487) has a Selling, General, & Admin. Expense of HK$282.5 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Cutia Therapeutics and its competitors.
Is Cutia Therapeutics' Selling, General, & Admin. Expense too high?
Cutia Therapeutics' current Selling, General, & Admin. Expense is HK$282.5 Mil. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Selling, General, & Admin. Expense compare to VRTX and REGN?
Cutia Therapeutics' Selling, General, & Admin. Expense of HK$282.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Cutia Therapeutics and its competitors. Cutia Therapeutics's current Selling, General, & Admin. Expense is HK$282.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$17.43, compared to a current price of HK$1.75 — trading 90% below its estimated fair value. The current Selling, General, & Admin. Expense is HK$282.5 Mil. Cutia Therapeutics' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Selling, General, & Admin. Expense is HK$282.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$1.75 is trading 90% below its estimated GF Value™ of HK$17.43.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
Selling, General, & Admin. Expense: HK$282.5 Mil
GF Value™: HK$17.43 vs. price of HK$1.75 (90% below fair value)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score
Get the complete analysis for HKSE:02487
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
